0830 GMT - Novo Nordisk's sales guidance is materially ahead of expectations, Intron Health's Naresh Chouhan writes. The company expects sales to grow 16%-24% this year with EBIT growing 19%-27%. Fourth-quarter EBIT beat expectations by 9% as the gross margin beat by 140 basis points and the EBIT margin beat by 170 basis points. "Given recent concerns on growth, we expect the shares to be up strongly this morning given the sales guidance is materially higher than consensus was expecting and Wegovy was in-line," Chouhan says. Shares trade 4.3% higher at 617.90 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 03:30 ET (08:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。